Raphael Sanches Peres

Raphael Sanches Peres

Auto-generated profile, based on publicly available information

Raphael Sanches Peres

Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
FAFlávio A. Amaral
Flávio A. Amaral
VCVivian V. Costa
Vivian V. Costa
LTLivia D. Tavares
Livia D. Tavares
Daniela SachsDaniela Sachs
Daniela Sachs
FCFernanda M. Coelho
Fernanda M. Coelho
MTMauro Martins Teixeira
Mauro Martins Teixeira
Objective: Deposition of monosodium urate monohydrate (MSU) crystals in the joints promotes an intense inflammatory response and joint dysfunction. This study evaluated the role of the NLRP3 inflammasome and 5‐lipoxygenase (5‐LOX)–derived leukotriene B4(LTB4) in driving tissue inflammation and hypernociception in a murine model of gout.Methods: Gout was induced by injecting MSU crystals into the joints of mice. Wild‐type mice and mice deficient in NLRP3, ASC, caspase 1, interleukin‐1β (IL‐1β), IL‐1 receptor type I (IL‐1RI), IL‐18R, myeloid differentiation factor 88 (MyD88), or 5‐LOX were used. Evaluations were performed to assess neutrophil influx, LTB4activity, cytokine (IL‐1β, CXCL1) production (by enzyme‐linked immunosorbent assay), synovial microvasculature cell adhesion (by intravital microscopy), and hypernociception. Cleaved caspase 1 and production of reactive oxygen species (ROS) were analyzed in macrophages by Western blotting and fluorometric assay, respectively.Results: Injection of MSU crystals into the knee joints of mice induced neutrophil influx and neutrophil‐dependent hypernociception. MSU crystal–induced neutrophil influx was CXCR2‐dependent and relied on the induction of CXCL1 in an NLRP3/ASC/caspase 1/IL‐1β/MyD88–dependent manner. LTB4was produced rapidly after injection of MSU crystals, and this was necessary for caspase 1–dependent IL‐1β production and consequent release of CXCR2‐acting chemokines in vivo. In vitro, macrophages produced LTB4after MSU crystal injection, and LTB4was relevant in the MSU crystal–induced maturation of IL‐1β. Mechanistically, LTB4drove MSU crystal–induced production of ROS and ROS‐dependent activation of the NLRP3 inflammasome.Conclusion: These results reveal the role of the NLRP3 inflammasome in mediating MSU crystal–induced inflammation and dysfunction of the joints, and highlight a previously unrecognized role of LTB4in driving NLRP3 inflammasome activation in response to MSU crystals, both in vitro and in vivo.

9 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RPRaphael Sanches Peres
Raphael Sanches Peres
FLFoo Y. Liew
Foo Y. Liew
JTJhimmy Talbot
Jhimmy Talbot
VCVanessa Carregaro
Vanessa Carregaro
RORene D. Oliveira
Rene D. Oliveira
FCFernando Q. Cunha
Fernando Q. Cunha
Significance: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). However, about 40% of patients are resistant to MTX. Furthermore, MTX resistance is only apparent after a prolonged continuous MTX treatment (>3 mo), by which time the disease of the nonresponders would have aggravated. Thus, there is a considerable unmet need for a biomarker to select MTX-resistant patients and place them immediately on alternative therapy. We found here that the low density of CD39 on peripheral regulatory T cells in RA patients is a rapid, convenient, and reliable ( P < 0.01) biomarker for MTX resistance. Our findings also provide previously unrecognized information on aspects of immune regulation in RA and the mechanism of action of MTX.

16 March 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
JTJhimmy Talbot
Jhimmy Talbot
FBFrancine J. Bianchini
Francine J. Bianchini
DNDanilele C. Nascimento
Danilele C. Nascimento
RORene D. R. Oliveira
Rene D. R. Oliveira
FSFabricio O. Souto
Fabricio O. Souto
JAJose C. Alves-Filho
Jose C. Alves-Filho
Objective: Infiltration of neutrophils into the joints plays an important role in bone erosion and articular destruction in rheumatoid arthritis (RA). Neutrophil trafficking during inflammation is a process that involves activation of chemotactic receptors. Recent findings suggest that changes in chemotactic receptor patterns could occur in neutrophils under certain inflammatory conditions. The aim of this study was to evaluate the gain of responsiveness of neutrophils to CCL2 in RA patients and to assess the role of CCL2 in driving neutrophil infiltration into the joints.Methods: Neutrophils were purified from the peripheral blood of patients with RA or from mice with antigen‐induced arthritis (AIA). Expression of CCR2 was evaluated using polymerase chain reaction, flow cytometry, and immunofluorescence analyses. In vitro chemotaxis to CCL2 was assayed to evaluate the functional significance of de novo CCR2 expression. The murine AIA model was used to evaluate the in vivo role of CCR2 in neutrophil infiltration into the joints.Results: High CCR2 expression and responsiveness to CCL2 were observed in neutrophils from the blood of patients with early RA and in neutrophils from the blood and bone marrow of mice with AIA. Genetic deficiency or pharmacologic inhibition of CCR2 protected against the infiltration of neutrophils into the joints. This protection was not associated with an impairment of the neutrophil chemotactic ability or CXC chemokine production in the joints. Moreover, adoptive transfer of wild‐type mouse neutrophils to CCR2‐deficient mice restored neutrophil infiltration and the articular mechanical hyperalgesia associated with joint inflammation.Conclusion: These findings suggest that CCR2 is directly involved in the detrimental infiltration of neutrophils into the joints in patients with RA, showing a new inflammatory role of CCR2 during RA flares or active disease.

12 June 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ASAndré L. Saraiva
André L. Saraiva
FVFlávio P. Veras
Flávio P. Veras
RPRaphael S. Peres
Raphael S. Peres
JTJhimmy Talbot
Jhimmy Talbot
KLKalil A. de Lima
Kalil A. de Lima
JAJose C. Alves-Filho
Jose C. Alves-Filho
Rheumatoid arthritis is a chronic inflammatory disease that leads to significant changes in metabolic activity. Succinate, an intermediate of the tricarboxylic acid cycle, has emerged as a metabolic mediator of the innate immune response. However, the involvement of succinate in the generation of the adaptive immune response and establishment of autoimmune response has not been addressed thus far. Here we demonstrated that the succinate‐sensing receptor (Sucnr1/GPR91) plays a critical role in the development of immune‐mediated arthritis. We found that Sucnr1 acts as a chemotactic gradient sensor that guides dendritic cells (DCs) into the lymph nodes, orchestrating the expansion of the Thelper(T h )17‐cell population and the development of experimental antigen‐induced arthritis. Sucnr1 −/− mice show reduced articular hyperalgesia, neutrophil infiltration and inflammatory cytokines in the joint, and reduced frequency of T h 17 cells in draining lymph nodes. Adoptive transfer of wild‐type (WT) DCs into Sucnr1 −/− mice restored the development of arthritis. Moreover, DC‐depleted mice transferred with Sucnr1 −/− DCs developed less arthritis than mice transferred with WT DCs. In contrast, succinate given together with the immunization boosted the recruitment of DCs and the frequency of T h 17 cells in draining lymph nodes, increasing arthritis severity. Therefore, the blockade of Sucnr1 may represent a novel therapeutic target of arthritis.—Saraiva, A. L., Veras, F. P., Peres, R. S., Talbot, J., de Lima, K. A., Luiz, J. P., Carballido, J. M., Cunha, T. M., Cunha, F. Q., Ryffel, B., Alves‐Filho, J. C. Succinate receptor deficiency attenuates arthritis by reducing dendritic cell traffic and expansion of Th17 cells in the lymph nodes. FASEB J. 32, 6550–6558 (2018). www.fasebj.org

8 June 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JTJhimmy Talbot
Jhimmy Talbot
RPRaphael S. Peres
Raphael S. Peres
LPLarissa G. Pinto
Larissa G. Pinto
RORene D. R. Oliveira
Rene D. R. Oliveira
KLKalil A. Lima
Kalil A. Lima
FCFernando de Queiroz Cunha
Fernando de Queiroz Cunha
Epidemiologic studies have highlighted the association of environmental factors with the development and progression of autoimmune and chronic inflammatory diseases. Among the environmental factors, smoking has been associated with increased susceptibility and poor prognosis in rheumatoid arthritis (RA). However, the immune and molecular mechanism of smoking-induced arthritis aggravation remains unclear. The transcription factor aryl hydrocarbon receptor (AHR) regulates the generation of Th17 cells, CD4 T cells linked the development of autoimmune diseases. AHR is activated by organic compounds including polycyclic aromatic hydrocarbons (PAHs), which are environmental pollutants that are also present in cigarette smoke. In this study, we investigated the role of AHR activation in the aggravation of experiment arthritis induced by exposure to cigarette smoke. Mice were exposed to cigarette smoke during the developmental phase of antigen-induced arthritis and collagen-induced arthritis to evaluate the effects of smoking on disease development. Aggravation of articular inflammation was assessed by measuring neutrophil migration to the joints, increase in articular hyperalgesia and changes in the frequencies of Th17 cells. In vitro studies were performed to evaluate the direct effects of cigarette smoke and PAH on Th17 differentiation. We also used mice genetically deficient for AHR (Ahr KO) and IL-17Ra (Il17ra KO) to determine the in vivo mechanism of smoking-induced arthritis aggravation. We found that smoking induces arthritis aggravation and increase in the frequencies of Th17 cells. The absence of IL-17 signaling (Il17ra KO) conferred protection to smoking-induced arthritis aggravation. Moreover, in vitro experiments showed that cigarette smoke can directly increase Th17 differentiation of T cells by inducing AHR activation. Indeed, Ahr KO mice were protected from cigarette smoke-induced arthritis aggravation and did not display increase in TH17 frequencies, suggesting that AHR activation is an important mechanism for cigarette smoke effects on arthritis. Finally, we demonstrate that PAHs are also able to induce arthritis aggravation. Our data demonstrate that the disease-exacerbating effects of cigarette smoking are AHR dependent and environmental pollutants with AHR agonist activity can induce arthritis aggravation by directly enhancing Th17 cell development.

19 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FVFlávio P. Veras
Flávio P. Veras
RPRaphael S. Peres
Raphael S. Peres
ASAndré L. L. Saraiva
André L. L. Saraiva
LPLarissa G. Pinto
Larissa G. Pinto
PLPaulo Louzada-Junior
Paulo Louzada-Junior
JAJose C. Alves-Filho
Jose C. Alves-Filho
Fructose 1,6-bisphosphate (FBP) is an endogenous intermediate of the glycolytic pathway. Exogenous administration of FBP has been shown to exert protective effects in a variety of ischemic injury models, which are attributed to its ability to sustain glycolysis and increase ATP production. Here, we demonstrated that a single treatment with FBP markedly attenuated arthritis, assessed by reduction of articular hyperalgesia, joint swelling, neutrophil infiltration and production of inflammatory cytokines, TNF and IL-6, while enhancing IL-10 production in two mouse models of arthritis. Our mechanistic studies showed that FBP reduces joint inflammation through the systemic generation of extracellular adenosine and subsequent activation of adenosine receptor A2a (A2aR). Moreover, we showed that FBP-induced adenosine generation requires hydrolysis of extracellular ATP through the activity of the ectonucleosides triphosphate diphosphohydrolase-1 (ENTPD1, also known as CD39) and ecto-5′-nucleotidase (E5NT, also known as CD73). In accordance, inhibition of CD39 and CD73 abolished anti-arthritic effects of FBP. Taken together, our findings provide a new insight into the molecular mechanism underlying the anti-inflammatory effect of FBP, showing that it effectively attenuates experimental arthritis by activating the anti-inflammatory adenosinergic pathway. Therefore, FBP may represent a new therapeutic strategy for treatment of rheumatoid arthritis (RA).